Prevention and reversal of type 1 diabetes--past challenges and future opportunities

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Over the past three decades there have been a number of clinical trials directed at interdicting the type 1 diabetes (T1D) disease process in an attempt to prevent the development of the disease in those at increased risk or to stabilize-potentially even reverse-the disease in people with T1D, usually of recent onset. Unfortunately, to date there has been no prevention trial that has resulted in delay or prevention of T1D. And, trials in people with T1D have had mixed results with some showing promise with at least transient improvement in β-cell function compared with randomized control groups, while others have failed to slow the decline in β-cell function when compared with placebo. This Perspective will assess the past and present challenges in this effort and provide an outline for potential future opportunities.

Original languageEnglish (US)
Pages (from-to)997-1007
Number of pages11
JournalDiabetes Care
Volume38
Issue number6
DOIs
StatePublished - Jun 1 2015

Fingerprint

Type 1 Diabetes Mellitus
Placebos
Clinical Trials
Control Groups

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Prevention and reversal of type 1 diabetes--past challenges and future opportunities. / Skyler, Jay S.

In: Diabetes Care, Vol. 38, No. 6, 01.06.2015, p. 997-1007.

Research output: Contribution to journalArticle

@article{80728a8903eb4fd6bc2a78ef13fa1dfd,
title = "Prevention and reversal of type 1 diabetes--past challenges and future opportunities",
abstract = "Over the past three decades there have been a number of clinical trials directed at interdicting the type 1 diabetes (T1D) disease process in an attempt to prevent the development of the disease in those at increased risk or to stabilize-potentially even reverse-the disease in people with T1D, usually of recent onset. Unfortunately, to date there has been no prevention trial that has resulted in delay or prevention of T1D. And, trials in people with T1D have had mixed results with some showing promise with at least transient improvement in β-cell function compared with randomized control groups, while others have failed to slow the decline in β-cell function when compared with placebo. This Perspective will assess the past and present challenges in this effort and provide an outline for potential future opportunities.",
author = "Skyler, {Jay S}",
year = "2015",
month = "6",
day = "1",
doi = "10.2337/dc15-0349",
language = "English (US)",
volume = "38",
pages = "997--1007",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "6",

}

TY - JOUR

T1 - Prevention and reversal of type 1 diabetes--past challenges and future opportunities

AU - Skyler, Jay S

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Over the past three decades there have been a number of clinical trials directed at interdicting the type 1 diabetes (T1D) disease process in an attempt to prevent the development of the disease in those at increased risk or to stabilize-potentially even reverse-the disease in people with T1D, usually of recent onset. Unfortunately, to date there has been no prevention trial that has resulted in delay or prevention of T1D. And, trials in people with T1D have had mixed results with some showing promise with at least transient improvement in β-cell function compared with randomized control groups, while others have failed to slow the decline in β-cell function when compared with placebo. This Perspective will assess the past and present challenges in this effort and provide an outline for potential future opportunities.

AB - Over the past three decades there have been a number of clinical trials directed at interdicting the type 1 diabetes (T1D) disease process in an attempt to prevent the development of the disease in those at increased risk or to stabilize-potentially even reverse-the disease in people with T1D, usually of recent onset. Unfortunately, to date there has been no prevention trial that has resulted in delay or prevention of T1D. And, trials in people with T1D have had mixed results with some showing promise with at least transient improvement in β-cell function compared with randomized control groups, while others have failed to slow the decline in β-cell function when compared with placebo. This Perspective will assess the past and present challenges in this effort and provide an outline for potential future opportunities.

UR - http://www.scopus.com/inward/record.url?scp=84947491087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947491087&partnerID=8YFLogxK

U2 - 10.2337/dc15-0349

DO - 10.2337/dc15-0349

M3 - Article

C2 - 25998292

AN - SCOPUS:84947491087

VL - 38

SP - 997

EP - 1007

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 6

ER -